Results 11 to 20 of about 10,168 (235)

Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. [PDF]

Semin Cancer Biol, 2018
Over the past few years, multiple immune checkpoint blockers (ICBs) have achieved unprecedented clinical success and have been approved by regulatory agencies for the treatment of an increasing number of malignancies. However, only a limited fraction of patients responds to ICBs employed as a standalone intervention, calling for the development of ...
Lhuillier C, Vanpouille-Box C, Galluzzi L, Formenti SC, Demaria S.   +4 more
europepmc   +6 more sources

Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. [PDF]

Cancer Cell, 2019
Although immune checkpoint blockers have yielded significant clinical benefits in patients with different malignancies, the efficacy of these therapies is still limited. Here, we show that disruption of transmembrane protein 176B (TMEM176B) contributes to CD8+ T cell-mediated tumor growth inhibition by unleashing inflammasome activation.
Segovia M, Russo S, Jeldres M, Mahmoud YD, Perez V, Duhalde M, Charnet P, Rousset M, Victoria S, Veigas F, Louvet C, Vanhove B, Floto RA, Anegon I, Cuturi MC, Girotti MR, Rabinovich GA, Hill M.   +17 more
europepmc   +10 more sources

Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs. [PDF]

Cancers (Basel), 2021
Background: Rodent cancer models have limitations in predicting efficacy, tolerability and accompanying biomarkers of ICIs in humans. Companion dogs suffering from neoplastic diseases have gained attention as a highly relevant translational disease model.
Pantelyushin S, Ranninger E, Guerrera D, Hutter G, Maake C, Markkanen E, Bettschart-Wolfensberger R, Rohrer Bley C, Läubli H, Vom Berg J.   +9 more
europepmc   +5 more sources

Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. [PDF]

Clin Cancer Res, 2018
Abstract The first evidence that radiotherapy enhances the efficacy of immune checkpoint blockers (ICB) was obtained a dozen years ago in a mouse model of metastatic carcinoma refractory to anti–CTLA-4 treatment. At the time, ICBs had just entered clinical testing, an endeavor that culminated in 2011 with the approval of the first anti ...
Vanpouille-Box C, Formenti SC, Demaria S.   +2 more
europepmc   +4 more sources

Understanding genetic determinants of resistance to immune checkpoint blockers

Seminars in Cancer Biology, 2020
The advent of immune checkpoint blockers (ICB) has revolutionized patient outcome in many tumor types. However, only a minority of patients truly benefits from these therapies and displays a durable and robust anti-tumor response that translates into improved outcome.
Sandrine, Aspeslagh, Roman M, Chabanon, Stéphane, Champiat, Sophie, Postel-Vinay   +3 more
exaly   +6 more sources

Alleviation of exhaustion-induced immunosuppression and sepsis by immune checkpoint blockers sequentially administered with antibiotics—analysis of a new mathematical model [PDF]

Intensive Care Medicine Experimental, 2019
Background Sepsis-associated immune dysregulation, involving hyper-inflammation and immunosuppression, is common in intensive care patients, often leading to multiple organ dysfunction and death.
Avi Gillis, Michael Beil, Karin Halevi-Tobias, Peter Vernon van Heerden, Sigal Sviri, Zvia Agur   +5 more
doaj   +2 more sources

Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience. [PDF]

Cancers (Basel)
Purpose: We report a 10-year experience in cancer therapy with concomitant treatment of percutaneous thermal ablation (PTA) and immune checkpoint blockers (ICBs). Material and methods: This retrospective cohort study included all patients at a single tertiary cancer center who had received ICBs at most 90 days before, or 30 days after, PTA. Feasibility
Bonnet B, Tournier L, Deschamps F, Yevich S, Marabelle A, Robert C, Albiges L, Besse B, Bonnet V, De Baère T, Tselikas L.   +10 more
europepmc   +3 more sources

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort. [PDF]

ESMO Open
Patients with solid organ transplant (SOT) and solid tumors are usually excluded from clinical trials testing immune checkpoint blockers (ICB). As transplant rates are increasing, we aimed to evaluate ICB outcomes in this population, with a special focus on lung cancer.We conducted a multicenter retrospective cohort study collecting real data of ICB ...
Remon J, Auclin E, Zubiri L, Schneider S, Rodriguez-Abreu D, Minatta N, Gautschi O, Aboubakar F, Muñoz-Couselo E, Pierret T, Rothschild SI, Cortiula F, Reynolds KL, Thibault C, Gavralidis A, Blais N, Barlesi F, Planchard D, Besse BMD.   +18 more
europepmc   +6 more sources

Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis

European Journal of Cancer, 2023
For patients with advanced thymic epithelial tumours (TET), there is no standard second-line treatment after platinum-based chemotherapy. Although immune checkpoint blockers (ICB) are a potential treatment strategy, their efficacy seems limited with an increased risk of immune-related adverse events (ir-AEs), thus hampering their application in daily ...
Jordi Remon, Guillermo Villacampa, Francesco Facchinetti, Massimo Di Maio, Florit Marcuse, Marcello Tiseo, Monique Hochstenbag, Lizza E.L. Hendriks, Benjamin Besse   +8 more
openaire   +6 more sources

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1 [PDF]

OncoImmunology, 2018
Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora has
Lisa Derosa, Bertrand Routy, Guido Kroemer, Laurence Zitvogel   +3 more
doaj   +2 more sources